Crossmark

Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies

Published Online: 2021-07-03

Published Print: 2021-06

Authors

Hu, Ke-jia

Yin, Elaine Tan Su

Hu, Yong-xian

Huang, He
License Information

Text and Data Mining valid from 2021-06-01

Version of Record valid from 2021-06-01
More Information

Article History

Received: 15 April 2021

Accepted: 16 June 2021

First Online: 3 July 2021

Conflict of Interest Statement

: The authors reported no potential conflict of interest relevant to this work.

Document is current